CAJ | 학술논문

目的探讨外源性给予成纤维细胞生长因子(FGF) 21对载脂蛋白E基因敲除(apoE-/-)小鼠动脉粥样硬化(AS)的影响及可能的机制.方法取17周龄C57 BL/6J小鼠12只作为空白对照组,将24只17周龄apoE-/-/小鼠采用随机数表法分为AS组和AS治疗组,每组各12只.采用皮下埋泵给药,AS治疗组给予FGF21(100 μg kg-1·d-1),其余2组给予等量生理盐水,给予高脂饮食喂养4周.药物干预4周后处死小鼠,分别于药物干预前和药物干预期间测定小鼠体质量和进食量.处死前微超声观察主动脉弓斑块面积及腹主动脉内径.药物干预4周后测定血脂及血浆中C反应蛋白(CRP)和肿瘤坏死因子(TNF)α的水平.用苏木素伊红、油红O染色观察主动脉弓内膜中膜厚度(IMT)及主动脉斑块面积.结果对照组小鼠主动脉未发现明显AS病变.AS组小鼠复合血脂指标总胆固醇(TC)/高密度脂蛋白胆固醇(HDL-C)比值、低密度脂蛋白胆固醇(LDL-C)/HDL-C比值及非HDL-C值、血浆CRP和TNFα水平均高于对照组(P均＜0.05).AS组小鼠主动脉IMT值高于对照组[(156.4±17.6) μm比(57.8±7.4) μm,P＜0.05].AS治疗组主动脉弓斑块面积低于AS组[(1.42±0.16) mm2比(2.30±0.10)mm2,P＜0.05],腹主动脉内径大于AS组[(0.97±0.03)mm比(0.75±0.18)mm,P＜0.05]；复合血脂指标TC/HDL-C(5.11±0.70比7.52±1.51)、LDL-C/HDL-C(3.90±0.76比5.77±1.27)及非HDL-C值[(6.33±1.22) mmol/L比(8.45±1.52)mmol/L]、血浆CRP[(4.20±1.03) mmol/L比(6.15±1.64) mmol/L]和TNFα[(1.29 ±0.47) mmol/L比(1.90±0.42)mmol/L]水平均低于AS组(P均＜0.05).AS治疗组小鼠主动脉IMT值[(107.2±33.5) μm比(156.4±17.6)μm]、主动脉斑块面积[(14.26±3.5)％比(23.06±4.16)％]及主动脉根部斑块面积[(21.75±7.14)％比(38.03±5.76)％]均小于AS组(P均＜0.05).结论 FGF21可以显著减轻AS病变,其机制可能是通过改善血脂异常,并抑制CRP和TNFα的表达延缓斑块进展.
목적 탐토외원성급여성섬유세포생장인자(FGF) 21대재지단백E기인고제(apoE-/-)소서동맥죽양경화(AS)적영향급가능적궤제.방법 취17주령C57 BL/6J소서12지작위공백대조조,장24지17주령apoE-/-/소서채용수궤수표법분위AS조화AS치료조,매조각12지.채용피하매빙급약,AS치료조급여FGF21(100 μg kg-1·d-1),기여2조급여등량생리염수,급여고지음식위양4주.약물간예4주후처사소서,분별우약물간예전화약물간예기간측정소서체질량화진식량.처사전미초성관찰주동맥궁반괴면적급복주동맥내경.약물간예4주후측정혈지급혈장중C반응단백(CRP)화종류배사인자(TNF)α적수평.용소목소이홍、유홍O염색관찰주동맥궁내막중막후도(IMT)급주동맥반괴면적.결과 대조조소서주동맥미발현명현AS병변.AS조소서복합혈지지표총담고순(TC)/고밀도지단백담고순(HDL-C)비치、저밀도지단백담고순(LDL-C)/HDL-C비치급비HDL-C치、혈장CRP화TNFα수평균고우대조조(P균＜0.05).AS조소서주동맥IMT치고우대조조[(156.4±17.6) μm비(57.8±7.4) μm,P＜0.05].AS치료조주동맥궁반괴면적저우AS조[(1.42±0.16) mm2비(2.30±0.10)mm2,P＜0.05],복주동맥내경대우AS조[(0.97±0.03)mm비(0.75±0.18)mm,P＜0.05]；복합혈지지표TC/HDL-C(5.11±0.70비7.52±1.51)、LDL-C/HDL-C(3.90±0.76비5.77±1.27)급비HDL-C치[(6.33±1.22) mmol/L비(8.45±1.52)mmol/L]、혈장CRP[(4.20±1.03) mmol/L비(6.15±1.64) mmol/L]화TNFα[(1.29 ±0.47) mmol/L비(1.90±0.42)mmol/L]수평균저우AS조(P균＜0.05).AS치료조소서주동맥IMT치[(107.2±33.5) μm비(156.4±17.6)μm]、주동맥반괴면적[(14.26±3.5)％비(23.06±4.16)％]급주동맥근부반괴면적[(21.75±7.14)％비(38.03±5.76)％]균소우AS조(P균＜0.05).결론 FGF21가이현저감경AS병변,기궤제가능시통과개선혈지이상,병억제CRP화TNFα적표체연완반괴진전.
Objective To explore the effects and related mechanisms of exogenous fibroblast growth factor(FGF) 21 on atherosclerosis in apolipoprotein E deficient(apoE-/-) mice.Methods Male 17-week-old C57BL/6J mice and apoE-/-mice were randomly divided into three groups (n =12 each):blank control group (C vehicle),atherosclerosis group without FGF21 (apoE-/-vehicle) and apoE-/-plus FGF21 (100 μg · kg-1 · d-1 subcutaneously treatment).All mice were fed with high-fat diet for 4 weeks.After 4 weeks treatments,atheroselerotic lesions in aortic arch and inner diameter of abdominal aorta were measured by ultrasonography.Plasma lipid profiles,CRP and TNFα were measured.The whole aorta and aortic root were prepared for HE and oil red O staining to analyze lesion areas.Results There was no evident plaque in C vehicle group.TC/HDL-C,LDL-C/HDL-C,non-HDL-C,expression of CRP and TNFα were significantly higher in apoE-/-vehicle group than in C vehicle group (all P ＜ 0.05).IMT of aorta [(156.4 ± 17.6) μm vs.(57.8 ±7.4) μm] were significantly higher in apoE-/-vehicle group than in C vehicle group (all P ＜ 0.05).While FGF21 significantly reduced the lesion area in aorta arch [(1.42 ± 0.16)mm2 vs.(2.30 ± 0.10) mm2,P ＜ 0.05] and the inner diameter of abdominal aorta [(0.97 ± 0.03) mm vs.(0.75 ± 0.18) mm,P ＜ 0.05] compared to apoE-/-vehicle group.Similarly,TC/HDL-C (5.11 ± 0.70),LDL-C/HDL-C (3.90 ±0.76),non-HDL-C[(6.33 ± 1.22) mmol/L],plasma CRP[(4.20 ± 1.03) mmol/L] and plasma TNFα[(1.29 ± 0.47) mmol/L] were also reduced by FGF21 (all P ＜ 0.05 vs.apoE-/-vehicle).Moreover,FGF21 decreased the IMT[(107.2 ± 33.5) μm vs.(156.4 ± 17.6) μm],lesion area of aorta [(14.26±3.5)％] vs.[(23.06 ±4.16)％] and plaque size of aorta root [(21.75 ±7.14)％ vs.(38.03 ± 5.76) ％] (all P ＜ 0.05 vs.apoE-/-vehicle).Conclusions FGF21 can protect apoE-/-mice from atherosclerosis by modifying lipid profiles and downregulating CRP and TNFα expressions.